Barclays PLC Pmv Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 30,248 shares of PMVP stock, worth $43,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,248

Previous 30,248 -0.0%

Holding current value

$43,557

Previous $45,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$1.44 - $1.69 $625,973 - $734,649	-434,704 Reduced 93.49%	30,248 $45,000
Q2 2024 Aug 14, 2024	SELL	$1.51 - $2.21 $43,182 - $63,201	-28,598 Reduced 5.79%	464,952 $753,000
Q1 2024 May 15, 2024	SELL	$1.51 - $3.12 $35,959 - $74,299	-23,814 Reduced 4.6%	493,550 $839,000
Q4 2023 Feb 15, 2024	BUY	$1.23 - $6.6 $57,012 - $305,923	46,352 Added 9.84%	517,364 $1.6 Million
Q3 2023 Nov 07, 2023	BUY	$6.01 - $8.93 $1.39 Million - $2.06 Million	230,692 Added 95.99%	471,012 $2.89 Million
Q2 2023 Aug 03, 2023	SELL	$3.94 - $6.27 $61,471 - $97,824	-15,602 Reduced 6.1%	240,320 $1.5 Million
Q1 2023 May 04, 2023	BUY	$4.77 - $9.16 $446,486 - $857,403	93,603 Added 57.67%	255,922 $1.22 Million
Q4 2022 Feb 13, 2023	SELL	$8.17 - $12.95 $257,779 - $408,598	-31,552 Reduced 16.27%	162,319 $1.41 Million
Q3 2022 Nov 03, 2022	BUY	$11.4 - $17.18 $810,768 - $1.22 Million	71,120 Added 57.94%	193,871 $2.31 Million
Q2 2022 Aug 12, 2022	BUY	$9.23 - $22.43 $1.05 Million - $2.56 Million	114,042 Added 1309.47%	122,751 $1.75 Million
Q1 2022 May 16, 2022	BUY	$14.86 - $23.55 $129,415 - $205,096	8,709 New	8,709 $182,000

Others Institutions Holding PMVP

# of Institutions

Shares Held

42.9M

Call Options Held

3.1K

Put Options Held

1.7K

View Full List

About PMV Pharmaceuticals, Inc.

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $65.7M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

More about PMVP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account